Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Moodys
Express Scripts
Dow
Medtronic
McKesson
Mallinckrodt

Last Updated: December 14, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Lebrikizumab

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for Lebrikizumab?

Lebrikizumab is an investigational drug.

There have been 20 clinical trials for Lebrikizumab. The most recent clinical trial was a Phase 3 trial, which was initiated on August 1st 2013.

The most common disease conditions in clinical trials are Asthma, Dermatitis, Atopic, and Dermatitis. The leading clinical trial sponsors are Hoffmann-La Roche, Genentech, Inc., and Dermira, Inc.

There are eleven US patents protecting this investigational drug and three hundred and twenty-seven international patents.

Recent Clinical Trials for Lebrikizumab
TitleSponsorPhase
A Study of Lebrikizumab in Patients With Moderate-to-Severe Atopic DermatitisDermira, Inc.Phase 2
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease (COPD)Hoffmann-La RochePhase 2
A Single-Arm Study to Evaluate Administration of Lebrikizumab by Participants or Caregivers in the Home SettingHoffmann-La RochePhase 3

See all Lebrikizumab clinical trials

Clinical Trial Summary for Lebrikizumab

Top disease conditions for Lebrikizumab
Top clinical trial sponsors for Lebrikizumab

See all Lebrikizumab clinical trials

US Patents for Lebrikizumab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Lebrikizumab   Start Trial Compositions and methods for treating plasma cell disorders and B-cell prolymphocytic disorders Knopp Biosciences LLC (Pittsburgh, PA)   Start Trial
Lebrikizumab   Start Trial Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein CureVac AG (Tubingen, DE)   Start Trial
Lebrikizumab   Start Trial Compositions and methods for treating chronic urticaria Knopp Biosciences LLC (Pittsburgh, PA)   Start Trial
Lebrikizumab   Start Trial Cholestosome vesicles for incorporation of molecules into chylomicrons THERASYN SENSORS, INC. (Eggertsville, NY)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Lebrikizumab

Drugname Country Document Number Estimated Expiration Related US Patent
Lebrikizumab Australia 2014287067 2033-07-12   Start Trial
Lebrikizumab Australia 2014306597 2033-07-12   Start Trial
Lebrikizumab Australia 2014306683 2033-07-12   Start Trial
Lebrikizumab Australia 2017276231 2033-07-12   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Baxter
Express Scripts
AstraZeneca
Johnson and Johnson
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.